Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Conference News SCAI 2021

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

Yael L. Maxwell

May 03, 2021

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Daily News

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

Caitlin E. Cox

October 08, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Yael L. Maxwell

October 16, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Todd Neale

August 17, 2018

Advertisement

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Chinese Registry Supports Prolonged DAPT Following PCI for ACS

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

TCTMD’s Top 10 Most Popular Stories for October 2019

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content